Jennifer Schneider’s insights on immunotherapy at JP Morgan 2025
When we think about patient stories and the patient journey, we often think about the long, complex saga of the chronic disease patient. But infectious disease, too, can be devastating for patients and families, especially when it strikes patients with an already weakened immune system.
Jennifer Schneider is the CEO of UK-based Centauri Therapeutics, which is developing an immunotherapy for infectious disease that can help patients who don’t respond well to traditional anti-microbials, often because of weakened immunity.
pharmaphorum editor-in-chief Jonah Comstock caught up with Schneider in San Francisco in January during the JP Morgan Healthcare Conference. In the video below, she tells him about their small team’s mission and some of the patient stories that keep them motivated.
She discusses the company’s technology and its plans for the coming year, and they also get into overall investment trends from the show and why anti-microbial resistance is just the tip of the iceberg when it comes to the problems with our dependence on antibiotics.
Check out the full conversation in this video.
